Renal outcomes after contrast exposure in patients with diabetes who use sodium–glucose cotransporter 2 inhibitors
Postgraduate Medical Journal · 2024
DOI: 10.1093/postmj/qgad118 ↗Kurz gefasst
Fachartikel in der Zeitschrift Postgraduate Medical Journal, 2024. Verfasst von Chih-Wei Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, 110, Taiwan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Taiwan Ministry of Science and Technology, Higher Education Sprout Project by the Ministry of Education, Taipei Medical University Hospital.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Contrast-induced nephropathy has become increasingly prevalent as the age and prevalence of comorbidities in the general population have increased. Most cases of contrast-induced nephropathy are reversible; however, some may progress to acute kidney disease, and subsequently, to chronic kidney disease. Sodium–glucose cotransporter 2 inhibitors (SGLT2i) are known for their renoprotective effects. However, whether the use of these inhibitors affects the risk of contrast-induced kidney injury remains unclear.
Methods
Data were collected from the Taipei Medical University Clinical Research Database. We included patients with diabetes who had contrast exposure between 2016 and 2020 because of computed tomography or coronary angiography. The primary outcome was the risk of a major adverse kidney event (MAKE), which encompassed acute kidney disease, chronic kidney disease progression, and the need for renal replacement therapy. Overlap weighting was performed to reduce the effects of potential confounders.
Results
This study included 12 421 patients, who were divided into two groups: SGLT2i users (n = 920) and nonusers (n = 11 501). The follow-up period after contrast exposure was 6 months. The risk of a MAKE was lower in SGLT2i users than in nonusers (incidence, 36.9 vs. 49.9 per 1000 person-months, respectively; P = .0011). Furthermore, the incidence of acute kidney disease or chronic kidney disease progression was significantly lower in the SGLT2i users than in nonusers. However, no significant between-group difference was noted in the incidence of other MAKEs.
Conclusions
SGLT2i may be safely used in diabetic patients needing contrast exposure. The risk of a MAKE may be lower in SGLT2i users than in nonusers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, 110, Taiwan.
- Division of Cardiology, Department of Internal Medicine and Cardiovascular Research Center, Taipei Medical University Hospital, Taipei, 110, Taiwan.
- Taipei Heart Institute, Taipei Medical University, Taipei, 110, Taiwan.
- Division of Cardiology, Department of Internal Medicine, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, 111, Taiwan.
- Research Information Section, Office of Information Technology, Taipei Medical University, Taipei, 110, Taiwan.
- Department of Pharmacy, Taipei Medical University Hospital, Taipei, 110, Taiwan.
ORCID-Profile: Ming-Tsang Chuang, Yi-Cheng Lin
Förderung
- Taiwan Ministry of Science and Technology
- Higher Education Sprout Project by the Ministry of Education
- Taipei Medical University Hospital
Zitieren
APA
Chen, C. W., Su, F. Y., Wang, P. P., Chuang, M. T., Lin, Y. C., Kao, C. C., & Huang, C. Y. (2024). Renal outcomes after contrast exposure in patients with diabetes who use sodium–glucose cotransporter 2 inhibitors. Postgraduate Medical Journal. https://doi.org/10.1093/postmj/qgad118
Vancouver
Chen CW, Su FY, Wang PP, Chuang MT, Lin YC, Kao CC, et al. Renal outcomes after contrast exposure in patients with diabetes who use sodium–glucose cotransporter 2 inhibitors. Postgraduate Medical Journal. 2024. doi:10.1093/postmj/qgad118
BibTeX
@article{Chen2024,
author = {Chen, Chih-Wei and Su, Fu-You and Wang, Ping-Ping and Chuang, Ming-Tsang and Lin, Yi-Cheng and Kao, Chih-Chin and Huang, Chun-Yao},
title = {Renal outcomes after contrast exposure in patients with diabetes who use sodium–glucose cotransporter 2 inhibitors},
journal = {Postgraduate Medical Journal},
year = {2024},
doi = {10.1093/postmj/qgad118}
}
EUVIMED